Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis

Chronic disability in multiple sclerosis is linked to neuroaxonal degeneration. 4-aminopyridine (4-AP) is used and licensed as a symptomatic treatment to ameliorate ambulatory disability in multiple sclerosis. The presumed mode of action is via blockade of axonal voltage gated potassium channels, th...

Full description

Bibliographic Details

Published in:	Brain (London, England : 1878) Vol. 143; no. 4; p. 1127
Main Authors:	Dietrich, Michael, Koska, Valeria, Hecker, Christina, Göttle, Peter, Hilla, Alexander M, Heskamp, Annemarie, Lepka, Klaudia, Issberner, Andrea, Hallenberger, Angelika, Baksmeier, Christine, Steckel, Julia, Balk, Lisanne, Knier, Benjamin, Korn, Thomas, Havla, Joachim, Martínez-Lapiscina, Elena H, Solà-Valls, Nuria, Manogaran, Praveena, Olbert, Elisabeth D, Schippling, Sven, Cruz-Herranz, Andrés, Yiu, Hao, Button, Julia, Caldito, Natalia Gonzalez, von Gall, Charlotte, Mausberg, Anne K, Stettner, Mark, Zimmermann, Hannah G, Paul, Friedemann, Brandt, Alexander U, Küry, Patrick, Goebels, Norbert, Aktas, Orhan, Berndt, Carsten, Saidha, Shiv, Green, Ari J, Calabresi, Peter A, Fischer, Dietmar, Hartung, Hans-Peter, Albrecht, Philipp
Format:	Journal Article
Language:	English
Published:	England 01.04.2020
Subjects:	4-aminopyridine optical coherence tomography multiple sclerosis NFAT experimental optic neuritis
ISSN:	1460-2156, 1460-2156
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!